Last week saw a number of broker notes hitting the wires once again. Three buy ratings that investors might want to be aware of are summarised below.
Here's why brokers think investors ought to buy them next week:
Allkem Ltd (ASX: AKE)
According to a note out of Goldman Sachs, its analysts have reiterated their buy rating on this lithium miner's shares with a slightly trimmed price target of $15.40. This follows the release of Allkem's first-half results, which came in slightly ahead of expectations. Allkem remains Goldman's preferred lithium exposure due to its discount to peers and its optionality across the Americas and Australia on the largest lithium resource under its coverage. The Allkem share price ended the week at $12.36.
Harvey Norman Holdings Limited (ASX: HVN)
Another note out of Goldman Sachs reveals that it analysts have retained their buy rating on this retail giant's shares with a trimmed price target of $4.70. Although Harvey Norman's first-half results fell short of expectations, Goldman remains positive for a number of reasons. This includes its dirt cheap valuation compared to peers and its belief that the peak cash drag on franchisee support is behind it. The Harvey Norman share price was fetching $3.71 at Friday's close.
Pointsbet Holdings Ltd (ASX: PBH)
Analysts at Bell Potter have retained their speculative buy rating on this sports betting company's shares with a reduced price target of $2.75. This follows a mixed half-year result with Pointsbet's revenue beating expectations but its loss coming in greater than forecast. Nevertheless, the broker remains positive given its very large opportunity in the North American sports betting market. The Pointsbet share price ended the week at $1.43.
